Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Glioblastoma
Interventions
DRUG

Sirolimus

Taken orally at different dose levels depending upon enrollment time period

DRUG

Vandetanib

Taken orally at different dose levels depending upon enrollment time period

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Instiute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Massachusetts General Hospital

OTHER